AU2004220274B2 - Allergen peptide fragments and use thereof - Google Patents

Allergen peptide fragments and use thereof Download PDF

Info

Publication number
AU2004220274B2
AU2004220274B2 AU2004220274A AU2004220274A AU2004220274B2 AU 2004220274 B2 AU2004220274 B2 AU 2004220274B2 AU 2004220274 A AU2004220274 A AU 2004220274A AU 2004220274 A AU2004220274 A AU 2004220274A AU 2004220274 B2 AU2004220274 B2 AU 2004220274B2
Authority
AU
Australia
Prior art keywords
seq
allergen
fragments
peptide
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2004220274A
Other languages
English (en)
Other versions
AU2004220274A1 (en
Inventor
Blaise Corthesy
Francois Spertini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Anergis SA
Original Assignee
Anergis SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anergis SA filed Critical Anergis SA
Publication of AU2004220274A1 publication Critical patent/AU2004220274A1/en
Assigned to ANERGIS SA reassignment ANERGIS SA Request for Assignment Assignors: UNIVERSITY OF LAUSANNE
Application granted granted Critical
Publication of AU2004220274B2 publication Critical patent/AU2004220274B2/en
Priority to AU2010212310A priority Critical patent/AU2010212310B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43531—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from mites
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C07K14/43572—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from bees

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Insects & Arthropods (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Botany (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Otolaryngology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
AU2004220274A 2003-03-14 2004-03-15 Allergen peptide fragments and use thereof Ceased AU2004220274B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2010212310A AU2010212310B2 (en) 2003-03-14 2010-08-12 Allergen peptide fragments and use thereof

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US45500403P 2003-03-14 2003-03-14
US60/455,004 2003-03-14
US10/799,514 US7923209B2 (en) 2003-03-14 2004-03-12 Allergen peptide fragments and use thereof
US10/799,514 2004-03-12
PCT/IB2004/001300 WO2004081028A2 (en) 2003-03-14 2004-03-15 Allergen peptide fragments and use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2010212310A Division AU2010212310B2 (en) 2003-03-14 2010-08-12 Allergen peptide fragments and use thereof

Publications (2)

Publication Number Publication Date
AU2004220274A1 AU2004220274A1 (en) 2004-09-23
AU2004220274B2 true AU2004220274B2 (en) 2010-05-13

Family

ID=33456828

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2004220274A Ceased AU2004220274B2 (en) 2003-03-14 2004-03-15 Allergen peptide fragments and use thereof
AU2010212310A Ceased AU2010212310B2 (en) 2003-03-14 2010-08-12 Allergen peptide fragments and use thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2010212310A Ceased AU2010212310B2 (en) 2003-03-14 2010-08-12 Allergen peptide fragments and use thereof

Country Status (6)

Country Link
US (5) US7923209B2 (cg-RX-API-DMAC7.html)
EP (4) EP2368574A1 (cg-RX-API-DMAC7.html)
JP (4) JP5389326B2 (cg-RX-API-DMAC7.html)
AU (2) AU2004220274B2 (cg-RX-API-DMAC7.html)
CA (2) CA2759072A1 (cg-RX-API-DMAC7.html)
WO (1) WO2004081028A2 (cg-RX-API-DMAC7.html)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7923209B2 (en) 2003-03-14 2011-04-12 Anergis, S.A. Allergen peptide fragments and use thereof
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
CA2702340C (en) 2006-10-12 2014-12-16 The University Of Queensland Compositions and methods for modulating immune responses
GB0710529D0 (en) 2007-06-01 2007-07-11 Circassia Ltd Vaccine
ITMI20072421A1 (it) * 2007-12-21 2009-06-22 Lofarma Spa Allergeni ed allergoidi da veleno d'api
WO2010089671A2 (en) * 2009-02-09 2010-08-12 Anergis S.A. Contiguous overlapping peptides for treatment of birch pollen allergy
JP5728678B2 (ja) * 2009-03-26 2015-06-03 国立大学法人名古屋大学 アレルギー疾患を診断するための方法
GB201002559D0 (en) * 2010-02-15 2010-03-31 Circassia Ltd Birch peptides for vaccine
US9724271B2 (en) 2010-04-30 2017-08-08 Allovate, Llc Methods and articles for preventing or reducing risk of developing a hyperallergenic immune system
JP6062851B2 (ja) * 2010-04-30 2017-01-18 アロヴェイト・エルエルシー 口腔粘膜を介してアレルギーを減感作するための方法、物品及びキット
BR112013010926A2 (pt) 2010-11-01 2016-08-23 Univ Technology Sidney agentes imunomoduladores e seus usos
EP2460824A1 (en) * 2010-12-01 2012-06-06 Biomay Ag Hypoallergenic polypeptides for the treatment of house dust mite allergy
EP2723373B1 (en) 2011-06-27 2017-06-21 Anergis S.A. Contiguous overlapping peptides for treatment of ragweed pollen allergy
KR102502640B1 (ko) 2012-08-21 2023-02-23 사노피 바이오테크놀로지 Il-4r 길항제의 투여에 의한 천식의 치료 또는 예방 방법
CN118286417A (zh) 2012-09-07 2024-07-05 瑞泽恩制药公司 以il-4r拮抗剂治疗特应性皮炎的方法
NZ707615A (en) 2012-10-30 2019-01-25 Aravax Pty Ltd Novel immunotherapeutic molecules and uses thereof
TWI755763B (zh) 2013-06-04 2022-02-21 美商再生元醫藥公司 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
JP6300907B2 (ja) * 2013-06-06 2018-03-28 アネルギ エスアー イエダニアレルギーの処置のための連続したオーバーラップペプチド
TWI634900B (zh) 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
US10485867B2 (en) 2013-09-19 2019-11-26 Allovate, Llc Toothpaste for delivery of allergens to oral mucosa
WO2015042664A1 (en) 2013-09-25 2015-04-02 Monash University Novel immunotherapeutic composition and uses thereof
IL315136A (en) 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4rantagonist
PT3110848T (pt) 2014-09-24 2024-03-05 Regeneron Pharma Métodos para tratamento de infeção cutânea por administração de um antagonista do il-4r
CA3246946A1 (en) 2014-11-14 2025-11-29 Sanofi Biotechnology Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist
US10232048B1 (en) 2014-11-18 2019-03-19 Divine Api-Logics, LLC Apitherapy method and composition
WO2017179025A1 (en) * 2016-04-15 2017-10-19 Alk-Abelló A/S Epitope polypeptides of ragweed pollen allergens
KR102872485B1 (ko) 2016-09-01 2025-10-20 리제너론 파아마슈티컬스, 인크. Il-4r 길항제를 투여함에 의해 알레르기를 예방하거나 치료하기 위한 방법
TWI784988B (zh) 2016-12-01 2022-12-01 美商再生元醫藥公司 治療發炎症狀的方法
WO2019028367A1 (en) 2017-08-04 2019-02-07 Regeneron Pharmaceuticals, Inc. METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES
PT3515465T (pt) 2017-08-18 2024-03-04 Regeneron Pharma Métodos para o tratamento de uma dermatite atópica grave mediante a administração de um inibidor de il-4r
US11034768B2 (en) 2017-10-30 2021-06-15 Sanofi Biotechnology Methods for treating or preventing asthma by administering an IL-4R antagonist
MX2020012064A (es) 2018-05-13 2021-04-13 Regeneron Pharma Metodos para tratar la dermatitis atopica administrando un inhibidor de il-4r.
WO2020121062A1 (en) 2018-12-12 2020-06-18 Anergis S.A. Methods of improving efficacy of allergy vaccines
KR20210143246A (ko) 2019-03-21 2021-11-26 리제너론 파아마슈티컬스, 인크. 알레르기 치료용 il-4/il-13 경로 억제제 및 형질 세포 절제의 병용
KR20220034878A (ko) 2019-07-16 2022-03-18 사노피 바이오테크놀로지 Il-4r 길항제를 투여하여 천식을 치료 또는 예방하는 방법
JP7736667B2 (ja) 2019-08-05 2025-09-09 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｉｌ－４ｒアンタゴニストを投与することによるアトピー性皮膚炎の治療方法
US11504426B2 (en) 2019-08-05 2022-11-22 Regeneron Pharmaceuticals, Inc. Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R antagonist

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4473495A (en) 1983-07-28 1984-09-25 Northwestern University Albumin-solubilized hymenoptera venoms for vaccine use
JP2993967B2 (ja) 1987-06-17 1999-12-27 インスティテュート・フォー・チャイルド・ヘルス・リサーチ ダニアレルゲンのクローニング
JP2594123B2 (ja) 1987-09-12 1997-03-26 株式会社林原生物化学研究所 減感作剤
US5152980A (en) 1988-05-19 1992-10-06 The Beth Israel Hospital Association Induction of tolerance to a foreign antigen IL-2 receptor-binding substances
US5124249A (en) 1989-11-28 1992-06-23 Khan Rashid H Method for evaluating protection to bee venom
US5565338A (en) 1990-06-04 1996-10-15 La Jolla Institute For Allergy And Immunology Suppressor T-cell hybridoma and production of allergen specific glycosylation inhibiting factor
US5965709A (en) 1991-08-14 1999-10-12 Genentech, Inc. IgE antagonists
IL105153A (en) 1992-03-25 1999-12-22 Immulogic Pharma Corp Therapeutic compositions comprising peptides derived from human t cell reactive feline protein
IT1254360B (it) 1992-05-11 1995-09-14 San Romanello Centro Fond Epitopi immunologicamente omologhi di hla e proteine del virus hiv.
US5582995A (en) 1993-06-11 1996-12-10 The General Hospital Corporation Methods of screening for compounds which inhibit the direct binding of Ras to Raf
US6074673A (en) 1996-04-22 2000-06-13 Guillen; Manuel Slow-release, self-absorbing, drug delivery system
AU9531698A (en) 1997-10-15 1999-05-03 Alk A/S Composition and method for treating an encephalomyelopathic, demyelinating or autoimmune disease
JP2002500198A (ja) 1998-01-09 2002-01-08 サーカシア リミテッド 脱感作のための方法及び組成物
GB2341389B (en) 1998-09-14 2000-07-12 Pan Pacific Pharmaceuticals In Useful properties of a bee venom protein and gene encoding same
FR2788698B1 (fr) 1999-01-27 2001-03-30 Commissariat Energie Atomique Peptides et proteines aptes a desensibiliser les sujets allergiques au venin d'abeille et compositions les contenant
US20030211510A1 (en) 1999-06-30 2003-11-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6780416B1 (en) 2000-02-18 2004-08-24 Ecole Polytechnique Federale De Lausanne Bee venom polypeptides and methods of use thereof
US20020193295A1 (en) 2001-05-04 2002-12-19 Emanuel Calenoff Immunogenic peptides and uses thereof
WO2004002415A2 (en) 2002-06-27 2004-01-08 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating a cytotoxic t lymphocyte immune response
US7923209B2 (en) 2003-03-14 2011-04-12 Anergis, S.A. Allergen peptide fragments and use thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ASTORI, M. et al., J. Immunol. 2000, Vol. 165, No. 6, pages 3497-3505 (X) *
KAEMMERER, R. et al., Clin. and Exp. Allergy, 1997, Vol. 27, No. 9, pages 1016-26 (X) *
SPERTINI, F. et al., J. Allergy and Clin Immunol. 2000, Vol. 105, No. 1 part 2, pages S378-S379 (X) *
VON GARNIER, C. et al., Europ. J. Immunol. Vol. 30, No. 6, 2000, pages 1638-45 (X) *

Also Published As

Publication number Publication date
EP1603591A2 (en) 2005-12-14
AU2010212310B2 (en) 2012-01-19
US7923209B2 (en) 2011-04-12
US20070110673A1 (en) 2007-05-17
US9193773B2 (en) 2015-11-24
JP2007001975A (ja) 2007-01-11
WO2004081028A2 (en) 2004-09-23
JP2013256520A (ja) 2013-12-26
JP2006520380A (ja) 2006-09-07
US8075897B2 (en) 2011-12-13
CA2519083A1 (en) 2004-09-23
CA2759072A1 (en) 2004-09-23
US8703144B2 (en) 2014-04-22
EP2204189A2 (en) 2010-07-07
US20140193444A1 (en) 2014-07-10
JP5389326B2 (ja) 2014-01-15
EP2687230A1 (en) 2014-01-22
JP2011201886A (ja) 2011-10-13
US20160095899A1 (en) 2016-04-07
US9808503B2 (en) 2017-11-07
EP2204189A3 (en) 2010-09-29
WO2004081028A3 (en) 2005-02-17
JP5390742B2 (ja) 2014-01-15
CA2519083C (en) 2017-06-13
US20040241178A1 (en) 2004-12-02
EP2368574A1 (en) 2011-09-28
AU2004220274A1 (en) 2004-09-23
AU2010212310A1 (en) 2010-09-02
US20120100167A1 (en) 2012-04-26

Similar Documents

Publication Publication Date Title
US9808503B2 (en) Allergen peptide fragments and use thereof for treatment of birch pollen allergies
JP2006520380A5 (cg-RX-API-DMAC7.html)
Himly et al. Art v 1, the major allergen of mugwort pollen, is a modular glycoprotein with a defensin‐like and a hydroxyproline‐rich domain
JP3554319B2 (ja) ペプチドｐ２７７類似体及びこれを含む糖尿病の治療又は診断のための薬剤組成物
WO1997033910A1 (en) Immunomodulatory peptides of vespid antigen 5
JPWO1997032600A1 (ja) アレルギー疾患に対するペプチド免疫療法剤
JPWO1997047648A1 (ja) Ｔ細胞エピトープペプチド
CN105120894A (zh) 新颖的免疫治疗分子和其用途
AU2012202084B2 (en) Allergen peptide fragments and use thereof
CN105992589A (zh) 新型免疫治疗组合物及其用途
US20090130130A1 (en) Mutant allergen(s)
CA2309387A1 (en) Method and kit for determining severe inflammatory reactions to mosquito bites
EP1224215B2 (en) NON-ANAPHYLACTIC FORMS OF GRASS POLLEN Ph1 p 6 ALLERGEN AND THEIR USE
Mohapatra et al. Therapeutic potential of recombinant allergens
JP4176820B2 (ja) スギ花粉アレルゲンＣｒｙｊＩＩエピトープ
Mistrello et al. Allergic diseases: state of the art and therapeutic perspectives
Kussebi protein for potential usage in allergen-specific immunotherapy. J. Allergy Clin. Immunol. 115, 323-329
Bayard Purification

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: ANERGIS SA

Free format text: FORMER APPLICANT(S): UNIVERSITY OF LAUSANNE

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: ADD COINVENTOR CORTHESY, BLAISE

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired